Evommune (EVMN) Income from Continuing Operations (2024 - 2026)
Evommune (EVMN) reported Income from Continuing Operations of 21674000.0 for Q1 2026, down 50.18% year-over-year from 43504752.16 in Q1 2025, and up 23.34% on a QoQ basis from 28273000.0 in Q4 2025.
Evommune (EVMN) has 3 years of Income from Continuing Operations data on file, last reported at 21674000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 50.18% year-over-year to 21674000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 76854000.0 (changed N/A YoY) and the FY2025 annual result came in at 77798000.0, down 16.45% from the prior year.
- Income from Continuing Operations rose to 21674000.0 in Q1 2026 per EVMN's latest filing, from 28273000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 12475000.0 in Q3 2025 and bottomed at 28273000.0 in Q4 2025.
- The 3-year median for Income from Continuing Operations is 18321000.0 (2024), against an average of 18916000.0.
- The widest annual swing landed in 2025, when Income from Continuing Operations increased 21.62%; it then plunged 50.18% in 2026.
- Tracing EVMN's Income from Continuing Operations over 3 years: stood at 20726000.0 in 2024, then tumbled by 36.41% to 28273000.0 in 2025, then gained by 23.34% to 21674000.0 in 2026.
- Per Business Quant, the three latest EVMN Income from Continuing Operations figures stand at 21674000.0 (Q1 2026), 28273000.0 (Q4 2025), and 12475000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Evommune | 782.16 Mn | 570.69 Mn | - | -21.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.67 Mn |
| Dec 31, 2025 | -28.27 Mn |
| Sep 30, 2025 | -12.48 Mn |
| Mar 31, 2025 | -14.43 Mn |
| Dec 31, 2024 | -20.73 Mn |
| Sep 30, 2024 | -15.92 Mn |